Adalimumab in the treatment of pediatric patients with chronic noninfectious anterior uveitis

References

• Päivönsalo-Hietanen T, Tuominen J, Saari KM. Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand. 2000;78(1):84–88.
   PubMedGoogle Scholar
• Clarke LA, Guex-Crosier Y, Hofer M. Epidemiology of uveitis in children over a 10-year period. Clin Exp Rheumatol. 2013;31(4):633–637.
   PubMed Web of Science ®Google Scholar
• Smith JA, Mackensen F, Sen HN, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009;116(8):1544–51, 51.e1.
   PubMed Web of Science ®Google Scholar
• Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California epidemiology of Uveitis study. Ophthalmology. 2004;111(3):491–500. discussion.
   PubMed Web of Science ®Google Scholar
• Rahimi M, Oustad M, Ashrafi A. Demographic and clinical features of pediatric uveitis at a tertiary referral center in Iran. Middle East Afr J Ophthalmol. 2016;23(3):237–240.
   PubMed Web of Science ®Google Scholar
• Al-Haddad C, BouGhannam A, Abdul Fattah M, et al. Patterns of uveitis in children according to age: comparison of visual outcomes and complications in a tertiary center. BMC Ophthalmol. 2019;19(1):137.
   PubMed Web of Science ®Google Scholar
• Cann M, Ramanan AV, Crawford A, et al. Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy. Pediatr Rheumatol Online J. 2018;16(1):51.
   PubMed Web of Science ®Google Scholar
• Jari M, Shiari R, Salehpour O, et al. Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):41.
   PubMed Web of Science ®Google Scholar
• Maccora I, Fusco E, Marrani E, et al. Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis. Rheumatology (Oxford). 2021 Feb 1;60(2):568-87.
   Google Scholar
• Carvounis PE, Herman DC, Cha S, et al. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol. 2006;244(3):281–290.
   PubMed Web of Science ®Google Scholar
• Skarin A, Elborgh R, Edlund E, et al. Long-term follow-up of patients with uveitis associated with juvenile idiopathic arthritis: a cohort study. Ocul Immunol Inflamm. 2009;17(2):104–108.
   PubMed Web of Science ®Google Scholar
• Kotaniemi K, Arkela-Kautiainen M, Haapasaari J, et al. Uveitis in young adults with juvenile idiopathic arthritis: a clinical evaluation of 123 patients. Ann Rheum Dis. 2005;64(6):871–874.
   PubMed Web of Science ®Google Scholar
• Acharya NR, Patel S, Homayounfar G, et al. Relapse of Juvenile idiopathic arthritis-associated uveitis after discontinuation of immunomodulatory therapy. Ocul Immunol Inflamm. 2019;27(4):686–692.
   PubMed Web of Science ®Google Scholar
• Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107–1117.
   PubMed Web of Science ®Google Scholar
• Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American college of rheumatology/arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Rheumatol. 2019;71(6):864–877.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Minden K, Tappeiner C, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum. 2019;49(1):43–55.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Klotsche J, Niewerth M, et al. Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany. Arthritis Res Ther. 2020;22(1):81.
   PubMed Web of Science ®Google Scholar
• Group SoUNSW, Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Clarke SL, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol Online J. 2016;14(1):27.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Roesel M, et al. Elevated laser flare values correlate with complicated course of anterior uveitis in patients with juvenile idiopathic arthritis. Acta Ophthalmol. 2011;89(6):e521–7.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Foeldvari I, Edelsten C, et al. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res (Hoboken). 2012;64(9):1365–1372.
   PubMed Web of Science ®Google Scholar
• Bou R, Adán A, Borrás F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int. 2015;35(5):777–785.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Michels H, Schumacher C, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012;32(5):1121–1133.
   PubMed Web of Science ®Google Scholar
• Little JA, Sen ES, Strike H, et al. The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhood. J Rheumatol. 2014;41(1):136–139.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–96.e3.
   PubMed Web of Science ®Google Scholar
• Sood AB, Angeles-Han ST. An update on treatment of pediatric chronic non-infectious uveitis. Curr Treatm Opt Rheumatol. 2017;3(1):1–16.
   PubMedGoogle Scholar
• Kalinina Ayuso V, Makhotkina N, Van Tent-hoeve M, et al. Pathogenesis of juvenile idiopathic arthritis associated uveitis: the known and unknown. Surv Ophthalmol. 2014;59(5):517–531.
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Calleja-Antolín S, Garzo-García I, et al. Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies. Ophthalmology. 2016;123(12):2618–2625.
   PubMed Web of Science ®Google Scholar
• Van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164–172.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637–1646.
   PubMed Web of Science ®Google Scholar
• Hawkins MJ, Dick AD, Lee RJ, et al. Managing juvenile idiopathic arthritis-associated uveitis. Surv Ophthalmol. 2016;61(2):197–210.
   PubMed Web of Science ®Google Scholar
• FDA. US Food & Drug Administration, full prescribing information. cited 2020 Nov 24. Available at: https://www.accessdata.fda.gov.
   Google Scholar
• National Institute for Health and Care Excellence. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis. cited 2020 Nov 11. Available at: https://www.nice.org.uk
   Google Scholar
• European Medicines Agency. European public assessment report: humira. cited 2020 Nov 11. Available at: https://www.ema.europa.eu
   Google Scholar
• Sen ES, Sharma S, Hinchcliffe A, et al. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease–a case cohort interventional study. Rheumatology (Oxford). 2012;51(12):2199–2203.
   PubMed Web of Science ®Google Scholar
• Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47(3):339–344.
   PubMed Web of Science ®Google Scholar
• Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149(4):572–575.
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol Online J. 2013;11:16.
   PubMed Web of Science ®Google Scholar
• Castiblanco C, Meese H, Foster CS. Treatment of pediatric uveitis with adalimumab: the MERSI experience. J AAPOS. 2016;20(2):145–147.
   PubMed Web of Science ®Google Scholar
• Díaz-Llopis M, Salom D, Garcia-de-vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119(8):1575–1581.
   PubMed Web of Science ®Google Scholar
• Bravo-Ljubetic L, Peralta-Calvo J, Noval S, et al. Adalimumab therapy for refractory childhood uveitis. J AAPOS. 2013;17(5):456–459.
   PubMed Web of Science ®Google Scholar
• García-De-Vicuña C, Díaz-Llopis M, Salom D, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm. 2013;2013:560632.
   PubMed Web of Science ®Google Scholar
• Magli A, Forte R, Navarro P, et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2013;251(6):1601–1606.
   PubMed Web of Science ®Google Scholar
• Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77(7):1003–1011.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Guly C. Adalimumab for childhood onset uveitis. Ann Rheum Dis. 2018;77(7):961–962.
   PubMed Web of Science ®Google Scholar
• Holland GN. A reconsideration of anterior chamber flare and its clinical relevance for children with chronic anterior uveitis (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2007;105:344–364.
   PubMedGoogle Scholar
• Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020;2(3):e135–e41.
   PubMedGoogle Scholar
• Tappeiner C, Mesquida M, Adán A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43(12):2183–2188.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol. 2017;69(3):668–675.
   PubMed Web of Science ®Google Scholar
• Quartier P. Tocilizumab in patients with juvenile idiopathic arthritis-associated uveitis. Lancet Rheumatol. 2020;2(3):E122–E3.
   Google Scholar
• Adán A, Llorenç V, Mesquida M, et al. Tocilizumab treatment for recalcitrant uveitic macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(9):2249–2250.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100(6):782–786.
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63(4):612–618.
   PubMed Web of Science ®Google Scholar
• Richards JC, Tay-Kearney ML, Murray K, et al. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol. 2005;33(5):461–468.
   PubMed Web of Science ®Google Scholar
• Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113(2):308–314.
   PubMed Web of Science ®Google Scholar
• Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113(5):860–4.e2.
   PubMed Web of Science ®Google Scholar
• Gallagher M, Quinones K, Cervantes-Castañeda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007;91(10):1341–1344.
   PubMed Web of Science ®Google Scholar
• Simonini G, Zannin ME, Caputo R, et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford). 2008;47(10):1510–1514.
   PubMed Web of Science ®Google Scholar
• Bickston SJ, Lichtenstein GR, Arseneau KO, et al. The relationship between infliximab treatment and lymphoma in Crohn’s disease. Gastroenterology. 1999;117(6):1433–1437.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–391.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Rigante D, et al. The presence of uveitis is associated with a sustained response to the interleukin (IL)-1 inhibitors anakinra and canakinumab in Behçet’s Disease. Ocul Immunol Inflamm. 2020;28(2):298–304.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191–197.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Cameli AM, et al. Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol. 2013;31(3 Suppl 77):152–153.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. 2015;34(7):1293–1301.
   PubMed Web of Science ®Google Scholar
• Sota J, Rigante D, Lopalco G, et al. Biological therapies for the treatment of Behçet’s disease-related uveitis beyond TNF-alpha blockade: a narrative review. Rheumatol Int. 2018;38(1):25–35.
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–787.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. The Lancet Rheumatology. 2020;2(6):e347-e357.
   Google Scholar
• A study of baricitinib (LY3009104) in participants from 2 years to less than 18 years old with active JIA-associated uveitis or chronic anterior antinuclear antibody-positive uveitis. ClinicalTrials.gov. Identifier: NCT04088409. cited 2020 Nov 25. Available at: https://clinicaltrials.gov
   Google Scholar
• Sakumura N, Shimizu M, Mizuta M, et al. Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis. Cytokine. 2018;110:459–465.
   PubMed Web of Science ®Google Scholar
• Spîrchez M, Samaşca G, Iancu M, et al. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients. Clin Lab. 2012;58(3–4):253–260.
   PubMed Web of Science ®Google Scholar
• Shoop-Worrall SJW, Wu Q, Davies R, et al. Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence, and new directions. Lancet Child Adolesc Health. 2019;3(10):725–733.
   PubMedGoogle Scholar
• Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 2010;303(13):1266–1273.
   PubMed Web of Science ®Google Scholar
• CLUSTER Consortium. cited 2020 Nov 20th. Available at: https://www.clusterconsortium.org.uk
   Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–2285.
   PubMed Web of Science ®Google Scholar
• Pereira R, Lago P, Faria R, et al. Safety of anti-TNF therapies in immune-mediated inflammatory diseases: focus on infections and malignancy. Drug Dev Res. 2015;76(8):419–427.
   PubMed Web of Science ®Google Scholar
• Baddley JW, Winthrop KL, Chen L, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis. 2014;73(11):1942–1948.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Contatore M, et al. Infection risk associated with anti-TNF-α agents: a review. Expert Opin Drug Saf. 2015;14(4):571–582.
   PubMed Web of Science ®Google Scholar
• Horton S, Jones AP, Guly CM, et al. Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the bristol participants of the SYCAMORE trial. Am J Ophthalmol. 2019;207:170–174.
   PubMed Web of Science ®Google Scholar
• Aquilani A, Marafon DP, Marasco E, et al. Predictors of flare following etanercept withdrawal in patients with rheumatoid factor-negative juvenile idiopathic arthritis who reached remission while taking medication. J Rheumatol. 2018;45(7):956–961.
   PubMed Web of Science ®Google Scholar
• Baszis K, Garbutt J, Toib D, et al. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. Arthritis Rheum. 2011;63(10):3163–3168.
   PubMed Web of Science ®Google Scholar
• Lerman MA, Lewen MD, Kempen JH, et al. Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors. Am J Ophthalmol. 2015;160(1):193–200.e1.
   PubMed Web of Science ®Google Scholar
• Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014;22(2):96–101.
   PubMed Web of Science ®Google Scholar
• Kalinina Ayuso V, Van De Winkel EL, Rothova A, et al. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol. 2011;151(2):217–222.
   PubMed Web of Science ®Google Scholar
• Acharya NR, Ebert CD, Kelly NK, et al. Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial. Trials. 2020;21(1):887.
   PubMed Web of Science ®Google Scholar
• Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106(4):685–698.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460–1468.
   PubMed Web of Science ®Google Scholar
• Vogelzang EH, Kneepkens EL, Nurmohamed MT, et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis. 2014;73(12):2178–2182.
   PubMed Web of Science ®Google Scholar
• Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137(5):1628–1640.
   PubMed Web of Science ®Google Scholar
• Kneepkens EL, Wei JC, Nurmohamed MT, et al. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann Rheum Dis. 2015;74(2):396–401.
   PubMed Web of Science ®Google Scholar
• Menting SP, Van Lümig PP, De Vries AC, et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. JAMA Dermatol. 2014;150(2):130–136.
   PubMed Web of Science ®Google Scholar
• Thomas SS, Borazan N, Barroso N, et al. Comparative immunogenicity of TNF Inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. a systematic review and meta-analysis. BioDrugs 2015;29(4):241–258.
   PubMed Web of Science ®Google Scholar
• Gorovits B, Baltrukonis DJ, Bhattacharya I, et al. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol. 2018;192(3):348–365.
   PubMed Web of Science ®Google Scholar
• Van Schouwenburg PA, Krieckaert CL, Nurmohamed M, et al. IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol. 2012;32(5):1000–1006.
   PubMed Web of Science ®Google Scholar
• Magill L, Adriani M, Berthou V, et al. Low percentage of signal regulatory protein α/β. Front Immunol. 2018;9:2865.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum. 2009;60(8):2541–2542.
   PubMed Web of Science ®Google Scholar
• Assa A, Matar M, Turner D, et al. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with crohn’s disease compared with reactive monitoring. Gastroenterology. 2019;157(4):985–96.e2.
   PubMed Web of Science ®Google Scholar
• Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol. 2021 Feb;17(2):81–97.
   PubMed Web of Science ®Google Scholar
• Franca R, Curci D, Lucafò M, et al. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. Expert Opin Drug Metab Toxicol. 2019;15(7):527–539.
   PubMed Web of Science ®Google Scholar
• Sam MJ, Connor SJ, Ng WW, et al. Comparative evaluation of 4 commercially available ELISA Kits for measuring adalimumab and anti-adalimumab antibodies. Ther Drug Monit. 2020;42(6):821–828.
   PubMed Web of Science ®Google Scholar
• Rocha C, Afonso J, Lago P, et al. Accuracy of the new rapid test for monitoring adalimumab levels. Therap Adv Gastroenterol. 2019;12:1756284819828238.
   Web of Science ®Google Scholar
• Cherry M, Dutzer D, Nasser Y, et al. Point-of-care assays could be useful for therapeutic drug monitoring of IBD Patients in a proactive strategy with adalimumab. J Clin Med. 2020;9(9):2739.
   PubMed Web of Science ®Google Scholar